Umbilical Cord Stem Cells for Skin Grafts in Donor Site Wounds
Skin Wound, Scar, Hypertrophic
About this trial
This is an interventional treatment trial for Skin Wound focused on measuring hUCMSC, Skin Wound, Scar, Hypertrophic, Stem cell
Eligibility Criteria
Inclusion Criteria: Patients between 18 and 60 years old with extensive scars, large benign tumors, or fresh wounds on the body surface. Patients who undergo medium-thickness skin graft surgery (donor site can be from the thigh, abdomen, or back). Participants who have a thorough understanding of the study objectives, significance, implementation plan, potential benefits, risks involved, measures to address risks, and the rights and obligations of the subjects (including privacy protection and the right to withdraw), and are willing to participate in this clinical study and can cooperate effectively. Exclusion Criteria: Participants who meet any of the following criteria are not suitable for inclusion: Hypertension, hypotension, heart disease (including history of myocardial ischemia, coronary heart disease, myocarditis). Liver or kidney dysfunction. Infectious diseases (including viral hepatitis, syphilis, HIV/AIDS, etc.). Venous thrombosis, thoracic or abdominal aortic aneurysm, aortic dissection. Blood disorders (abnormal coagulation function, anemia, leukemia, polycythemia vera, aplastic anemia, etc.). Allergic conditions (urticaria, bronchial asthma, history of allergic reactions to two or more drugs or foods). Respiratory system diseases (chronic bronchitis, emphysema, bronchiectasis, respiratory failure, chronic obstructive pulmonary disease, interstitial pneumonia). Digestive system diseases (severe gastric or duodenal ulcers, chronic gastritis, chronic pancreatitis). Urinary system diseases (chronic urinary tract infections, nephritis, nephrotic syndrome). Endocrine system diseases (hyperthyroidism, diabetes, acromegaly, pituitary diseases, adrenal diseases, diabetes insipidus). Organic neurological disorders or psychiatric illnesses (encephalitis, sequelae of traumatic brain injury, epilepsy, schizophrenia, hysteria, depression, severe insomnia, neurasthenia). Chronic skin diseases (especially infectious, allergic, and inflammatory systemic skin diseases, such as extensive eczema, pemphigus, pemphigoid). Autoimmune diseases and collagen diseases (such as systemic lupus erythematosus, dermatomyositis, scleroderma). History of long-term smoking, alcohol abuse, or drug addiction. History of major surgeries (such as gastric, lung, splenic, renal, or liver resection). History of other significant malignant tumors. Blood donation or organ transplantation within the past 5 years. Pregnancy, lactation, menstrual period, or within 1 year after termination of pregnancy. Previous circumstances of being rejected for voluntary blood donation. Other situations deemed unsuitable for participation in this study by the investigators.
Sites / Locations
- ChenxiaosongRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
human umbilical cord mesenchymal stem cells
blank solvent
Injection of human umbilical cord mesenchymal stem cells (hUCMSC) into the donor site. Dosage of stem cell preparation: Calculated based on the area of the donor site, with a cell count of 1X10^5cells/cm2. Administration method: The cells are prepared as an injectable suspension using a blank solvent for stem cells at a concentration of 1X10^6 cells/ml (0.1 ml/cm2). Timing of administration: Administered immediately after completion of the donor site harvesting procedure. Treatment duration: The stem cell administration is a single dose, administered at the specified timing as described above
Injection of an equal volume of blank solvent for suspension of stem cells into the donor site. Dosage of Control group preparation: Calculated based on the area of the donor site. Administration method: Injection of an equal volume of blank solvent for suspension of stem cells into the donor site. Timing of administration: Administered immediately after completion of the donor site harvesting procedure. Treatment duration: The Control group administration is a single dose, administered at the specified timing as described above